United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aflac

Con Ed

Intel

MDU Resources Group

J. M. Smucker

Vanguard High Dividend Yield ETF

Verizon

My dividend stock portfolio was burnt by dividend cuts in 2020 and lost over $800+ in forward dividend income. Therefore, I was ready to get back to basics and acquire more shares in the best quality dividend stocks out there. I make a weekly purchase of 3 shares into the Vanguard High Dividend Yield ETF. There were no special opportunities/large drops in the market, therefore I only bought on Mondays throughout December.

Dividend Stock Purchase: Lanny's December 2020 Summary

ROCKLAND, Mass. and NEW YORK, Jan. 25, 2021 /PRNewswire/ -- EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for...

European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

BioNTech SE

The COVID-19 vaccine made by Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) has been approved by Australia's Therapeutic Goods Administration, Reuters reported Monday (Sydney Time). What Happened: Inoculation of Pfizer's vaccine is likely to commence in late February at 80,000 doses per week, Australia's Health Minister Greg Hunt told reporters.

Pfizer COVID-19 Vaccine Gets Approved In Australia

Several factors should work in the big drugmaker's favor this year.

Why Pfizer's Future Looks Better in 2021

White House chief of staff Ron Klain said Sunday that he didn't think it was possible for states to purchase Covid-19 vaccines directly from manufacturers.

White House says U.S. states can't directly purchase Covid vaccine under emergency use authorization

Pfizer CEO Albert Bourla knows what he wants.

What Kind of Deals Is Pfizer Planning for the Next Few Years?

Gilead Sciences

One has a top COVID-19 treatment, the other has a top COVID-19 vaccine. Which stock will come out on top.

Better Buy: Gilead Sciences vs. Pfizer

Pfizer's Covid-19 vaccine is authorized for people age 16 and older. The company's trial in kids 12-15 is now fully enrolled, a key step for use in kids.

Pfizer says its Covid vaccine trial for kids ages 12 to 15 is fully enrolled

AstraZeneca

Bank of America

Johnson & Johnson

Moderna

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis

The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.

CDC quietly changes Covid vaccine guidance to OK mixing Pfizer and Moderna shots in 'exceptional situations'

Pfizer will supply up to 40 million doses of its coronavirus vaccine to a global alliance aiming to provide poor nations with coronavirus vaccines, the World Health Organization said Friday.

Pfizer to supply up to 40 million doses to WHO-backed global Covid vaccine program

BioNTech SE and Pfizer Inc. said Friday that they plan to sell 40 million doses of their COVID-19 vaccine this year to Covax, a group that aims to ensure 92 lower-income countries have access to coronavirus vaccines. BioNTech's stock gained 1.2% in trading on Friday, while shares of Pfizer were up 0.3%.

BioNTech, Pfizer to sell 40 million doses to lower-income countries

NEW YORK CITY, NY and MAINZ, GERMANY, January 22 , 2021 (GLOBE NEWSWIRE) — Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.

Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19

Norway's medicines authority said there might be a link between vaccination and the deaths of several elderly people.

WHO Says Pfizer-BioNTech Covid-19 Vaccine Is Safe For The Elderly After Norway Questioned Its Role In Numerous Deaths

Apple

Mastercard

The billionaire investor seems likely to add to his already impressive net worth with these stocks.

3 Warren Buffett Stocks That Should Be Surefire Winners in 2021

GlaxoSmithKline

In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration. What Happened: The injectable — Cabenuva — is designed to replace the current treatment of HIV in adults which is based on taking daily pills.

Pfizer, GSK-Backed ViiV First To Get FDA Approval For Injectable Drug To Treat HIV

The partners could supply the WHO with coronavirus vaccine doses for lower-income countries.

Pfizer and BioNTech to Supply WHO's COVID-19 Vaccine Program

PFE stock never enjoyed the same run-up in the Covid-19 vaccine race as its competitors, even though it crossed the finish line first. The post For Pfizer, the Covid-19 Vaccine ‘Honeymoon' Is Over appeared first on InvestorPlace.

For Pfizer, the Covid-19 Vaccine ‘Honeymoon' Is Over

Pfizer stock has been struggling mainly due to misapprehensions surrounding the company's Covid-19 vaccine and the depth of its portfolio. The post Ignore the Bears and Invest in Pfizer appeared first on InvestorPlace.

Ignore the Bears and Invest in Pfizer

Pfizer (PFE) and partner BioNTech announce data from an in-vitro study showing that their coronavirus vaccine holds potential for neutralization of the new strain of coronavirus that was found in the United Kingdom.

Pfizer (PFE) COVID-19 Vaccine Seems Potent Against UK Strain

Abbott Labs

3 COVID Stocks to Buy if You're Not a Big Risk-Taker

A new study bolsters confidence in the mRNA vaccine.

Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant

Novavax

Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making the Biggest Headlines Today appeared first on InvestorPlace.

Covid-19 Vaccine Roundup: 5 Pharma Stocks Making the Biggest Headlines Today

The coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) works against a new strain of coronavirus that appeared in the U.K., according to a preprint made available before publication. What Happened: The B.1.1.7 strain is unlikely to escape BNT162b2-mediated protection, according to the preprint.

Pfizer-BioNTech Vaccine Found Effective Against New Coronavirus Strain In Lab Study

Amgen

Cerner

Merck

Stryker

UnitedHealth Group

Health Care Select Sector SPDR Fund

Politics is a wildcard that can negatively impact healthcare stocks. But there are still many top companies with great prospects to consider.

News for Pfizer Stock (PFE)